How much is the estimated monthly cost of Osimertinib/Tagrisso targeted treatment?

Osimertinib is a targeted therapy drug mainly used to treat patients with non-small cell lung cancer (NSCLC) carrying EGFR gene mutations. Its application in the adjuvant treatment of early-stage non-small cell lung cancer and the treatment of metastatic non-small cell lung cancer has been widely recognized. Osimertinib is administered as 80 mg orally once daily, and patients typically take the drug until disease relapses, unacceptable toxicity occurs, or for up to three years.

In the domestic market, the prices of original drugs vary depending on the manufacturer and relevant policies. According to the current market conditions, the common specifications of osimertinib are 80mg/30 tablets and 40mg/30 tablets, with the price ranging from RMB 4,000 to RMB 6,000. This means that when patients take osimertinib, the monthly cost is approximately 4,000 to 6,000 yuan, and the specific cost depends on the specifications and source of the drug purchased.

In addition, some generic drugs have appeared in the international market, especially in some developing countries such as Laos and Bangladesh. These generic drugs contain the same active ingredients as the brand-name drugs and have similar effects, but are relatively less expensive. For example, the price of generic drugs of 80mg/30 tablets may be around RMB 800, providing patients with a more economical choice. However, when choosing to use a generic drug, patients should carefully consider the source and quality of the drug to ensure the safety and effectiveness of their treatment.

Overall, the cost of osimertinib is one of the important factors that patients with non-small cell lung cancer need to consider during treatment. Although the original drug is more expensive, it is still widely used due to its remarkable efficacy. At the same time, the emergence of generic drugs has provided patients with more choices and reduced the burden of treatment. Before receiving treatment, patients should fully communicate with their doctors and evaluate their own situation to choose the most appropriate treatment plan, balance the efficacy and economic burden, and ultimately achieve the best treatment effect.

Reference materials:https://go.drugbank.com/drugs/DB09330